-
COVID-19 Case Analysis 23 Jan to 29 March 2020
- posted by: Lee Smith
- posted on: March 30, 2020
Animated bubble plot of cumulative COVID-19 cases & deaths by country.
Read the rest of this post -
Hope for Chlamydia STI Vaccine After Promising Initial Results
- posted by: Lee Smith
- posted on: November 4, 2019
A vaccine to protect against Chlamydia has taken a step closer to licensure after successful phase 1 clinical trials. The clinical studies were performed at Imperial College London and demonstrated the safety of the vaccine.
Read the rest of this post -
CEPI awards up to US$21 million to Themis Bioscience for Phase 3 Chikungunya Vaccine Development
- posted by: Lee Smith
- posted on: June 5, 2019
CEPI awards US$21 million to Themis Bioscience
Read the rest of this post -
Themis Bioscience Receives FDA Fast Track Designation for Chikungunya Vaccine Candidate
- posted by: Lee Smith
- posted on: February 25, 2019
Chikungunya Vaccine receives FDA Fast Track Designation
Read the rest of this post -
FluGen’s M2SR Influenza Vaccine Succeeds in Phase 2 Human Challenge Trial
- posted by: Lee Smith
- posted on: February 13, 2019
FluGen’s Influenza Vaccine Succeeds in Phase 2 Human Challenge Trial
Read the rest of this post -
Takeda Vaccine's Dengue Vaccine meets Primary Endpoints in its Phase III Efficacy Trial
- posted by: Lee Smith
- posted on: January 30, 2019
Takeda Vaccine's Dengue Vaccine meets its Primary Endpoints in Phase III Efficacy Trial.
Read the rest of this post -
Thoughts from the World Vaccine Congress, Washington 2018
- posted by: Lee Smith
- posted on: April 3, 2018
I'm currently attending the World Vaccine Congress 2018 in Washington to hear the latest musing from the sector's thought leaders and also find out about the latest technologies that are being used in the production of vaccines globally.
Read the rest of this post -
Themis Bioscience Enters into a $37.5m Agreement with CEPI to Develop a Lassa Fever and MERS-CoV Vaccine
- posted by: Lee Smith
- posted on: March 7, 2018
Themis Bioscience GmbH, an Austrian based vaccine company, has secured a $37.5m agreement with CEPI to create new vaccines for the infectious diseases Lassa Fever and MERS-CoV.
Read the rest of this post -
Chikungunya Vaccine UK Government Funding Secured By Themis Bioscience
- posted by: Lee Smith
- posted on: September 12, 2017
One year ago in September 2016 the UK's government innovation agency Innovate UK provided £1 million to help accelerate Themis' Zika candidate into the clinic. Now, a year on they are providing another £3 million for clinical trials to help propel the firm's Chikungunya vaccine forward.
Read the rest of this post